MayoComplete Sarcoma Mutation Panel, Next-Generation Sequencing, Tumor
Use
This test is primarily used for identifying mutations that aid in the diagnosis of specific soft tissue and bone tumors, such as sarcoma. It also identifies mutations with prognostic or therapeutic significance and assesses microsatellite instability to support immunotherapy decisions.
Special Instructions
A pathology report containing patient name, block number, tissue collection date, and source of the tissue is necessary for testing. Specimen preparation should adhere to specific guidelines, avoiding decalcification and ensuring adequate tumor nuclei content.
Limitations
This test cannot differentiate between somatic and germline alterations. A negative result does not exclude the presence of variants below the detection limit. It cannot detect multi-exon deletions, large genomic copy number variants, or epigenetic modifications such as promoter methylation. Results should be interpreted in the context of comprehensive clinical and laboratory data.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
LOINC Codes
- 73977-1
- 82939-0
- 69047-9
- 48767-8
- 31208-2
- 80398-1
- 85069-3
- 62364-5
- 18771-6
Result Turnaround Time
12-20 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Not provided
Minimum Volume
36 mm(2)
Container
Formalin-fixed, paraffin-embedded tissue block
Collection Instructions
Submit a formalin-fixed, paraffin-embedded tissue block with an acceptable amount of tumor tissue.
Causes for Rejection
Improper fixation with agents such as decalcification may cause PCR failure.